← Evidence map

ArticleBMJ (Clinical research ed.)2002

Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.

Brian R BudenholzerPubMed ↗Full text ↗

No numbers read from the abstract.

2 papers cite it

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

this papercites it

Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs. | OpenQuestion